Post-Transplant Malignancy: Treatments

Tuesday, May 21, 2024 - 14:00 to 15:00

REGISTER

After participating in this webinar, the attendee will be able to:

  1. Update knowledge on the epidemiology of post-transplant cancer.
  2. Illustrate examples of comprehensive, integrated cancer and transplant clinic.
  3. Review the updated data on cancer therapies for post-transplant cancers (e.g. immunotherapy and cellular therapies).

Speakers:

  • Naoka Murakami, MD, PhD, FAST • Assistant Professor, Harvard Medical School, Brigham and Women’s Hospital, Boston, MA
  • Chris Blosser, MD, FAST • Professor, University of Washington, Fred Hutch Cancer Center and Seattle Children’s Hospital, Seattle, WA

Moderator:

  • Kenar Jhaveri, MD • Professor in Medicine, Northwell Health, New Hyde Park, NY
- - - - -

The AST Education Committee would like to thank the Thoracic and Critical Care Community of Practice (TCC COP), Kidney Pancreas Community of Practice (KPCOP), Liver and Intestinal Community of Practice (LICOP) and others for suggesting the core topic of "Post-Transplant Malignancy" as part of the 2023-2024 T3 webinar series. Learn more about AST's COPs at www.myast.org/cops .

Series category: 
T3: Timely Topics in Transplantion

Educational Content Disclaimer: The content, information, opinions, and viewpoints contained in educational materials housed on and linked from the AST web site are those of the authors or contributors of such materials. While the AST and its committees take great care to screen the credentials of the contributors and make every attempt to review the contents, AST MAKES NO WARRANTY, EXPRESSED OR IMPLIED, as to the completeness or accuracy of the content contained in the educational materials or on this website. The reader of these materials uses these materials at his or her own risk, and AST shall not be responsible for any errors, omissions, or inaccuracies in these materials, whether arising through negligence, oversight, or otherwise. Reliance on any information appearing on this site is strictly at your own risk. Read the full disclaimer.